Major Chinese plasma-products and vaccine maker, producing albumin, immunoglobulin and influenza and other vaccines.
Major Chinese plasma-products and vaccine maker, producing albumin, immunoglobulin and influenza and other vaccines.
Sells albumin and immunoglobulin made from collected plasma, so output depends on how much its state-licensed collection stations can gather, and regulators cap new station licences. Vaccines, led by flu shots, are a second income line with seasonal demand through disease-control centres and hospitals.
In one line: A Chinese CSL/Grifols plus a vaccine business.
Moat: narrow (regulatory licence, scale). One of China's largest plasma-collection networks, capacity that is capped and licensed by the state.
Headquarters: Xinxiang, China · Employees: 4,117
Size Hualan Biological Engineering (002007.SZ) is a China Health Care company (Biotechnology) with a market value of $3.20B, the 753rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.80 on 18 Nov 2026.
Performance Over six months the shares fell 16.8%, against +5.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 10.8% over the last twelve months (peer median +8.9%); the operating margin is 16.9% (peer median -3.2%).
Valuation It trades at 26.7× forward earnings against a peer median of 31.3× (4th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points below its cost of capital (8.6% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.80B | CN¥4.58B | CN¥4.36B | CN¥5.32B | CN¥4.50B |
| Revenue growth | — | +5% | -18% | +18% | — |
| Gross profit | CN¥1.98B | CN¥2.51B | CN¥2.56B | CN¥3.59B | CN¥2.84B |
| EBITDA | n/a | CN¥1.41B | CN¥1.45B | CN¥2.08B | CN¥1.51B |
| Net income | CN¥587M | CN¥940M | CN¥1.09B | CN¥1.48B | CN¥1.08B |
| Free cash flow | CN¥804M | CN¥945M | CN¥939M | CN¥680M | CN¥632M |
| Capital expenditure | CN¥181M | CN¥197M | CN¥256M | CN¥753M | CN¥394M |
| Total debt | CN¥628M | CN¥547M | CN¥1.01B | CN¥1.01B | CN¥1.13B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hualan Biological Engineering 002007.SZ | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% |
| Shanghai RAAS Blood Products 002252.SZ | $4.57B | -15% | -22% | 17% | 12.8× | n/a |
| Beijing Tiantan Biological Products 600161.SS | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% |
| CSL CSL.AX | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% |
| Grifols GRF.MC | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002007.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.2% | -4.6% | 7th lowest of 21 |
| 6-month return | -16.8% | +5.5% | 3rd lowest of 21 |
| Distance from 52-week high | -30.6% | -27.8% | 10th lowest of 21 |
| Revenue growth (TTM) | -10.8% | +8.9% | 4th lowest of 17 |
| Operating margin | 16.9% | -3.2% | 5th highest of 17 |
| Forward P/E | 26.7× | 31.3× | 4th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 15.8% | 2.2% | 2nd most demanding of 6 |
| Growth delivered (Del g) | -1.8% | +27.4% | lowest of 6 |
| Hurdle (Req g minus delivered) | +17.6 pp | -31.7 pp | most demanding of 6 |
| ROIC minus cost of capital | -2.9 pp | -9.4 pp | 7th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% | -1.8% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% | +9.4% |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% | +70.2% |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% | +12.5% |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | n/a | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $3.67B | -6% | +12% | -4% | 29.4× | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |